Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 vs T-DM1 in HER2-positive Breast Cancer
NCT06316531Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in HER2-positive breast cancer, sponsored by Biokin Pharmaceutical. Started May 2024; status: active, not recruiting.
02
Drugs
BL-M07D1
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06316531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316531.